Elixiron Reports Positive Phase 2 Interim Results for Alzheimer's Drug Candidate Enrupatinib

Elixiron Immunotherapeutics has announced encouraging interim results from its ongoing Phase 2 proof-of-concept study evaluating enrupatinib (EI-1071), an investigational treatment for Alzheimer's disease.

The company is developing enrupatinib as a brain-penetrant oral therapy designed to target neuroinflammation, a process increasingly recognized as an important contributor to Alzheimer's disease progression. The study is supported by the Alzheimer's Association through its Part the Cloud program.

The latest findings showed favorable safety and tolerability, evidence that the drug is reaching its intended target in the brain, and early signs that reducing neuroinflammation may lead to cognitive benefits in certain patients.

Why Neuroinflammation Matters in Alzheimer's Disease

When most people think about Alzheimer's disease, they usually think about amyloid plaques and tau tangles. However, researchers now understand that neuroinflammation also plays a major role in disease progression.

Inflammation in the brain can worsen damage caused by amyloid and tau, accelerating cognitive decline. Because of this, scientists have been searching for ways to safely reduce harmful inflammation in the brain.

Enrupatinib was specifically designed to address this challenge by targeting colony-stimulating factor 1 receptor (CSF-1R), a key regulator of microglial activity and neuroinflammatory responses.

Positive Safety Results Observed

One of the most important findings from the interim analysis was the favorable safety profile of enrupatinib.

Among all evaluable participants in the study, no drug-related serious adverse events were reported. Researchers also noted that no clinically significant liver toxicity was observed.

This finding is particularly important because some earlier drugs targeting the same pathway have faced concerns regarding liver-related side effects. The current data suggest that enrupatinib may be suitable for long-term treatment, which is essential for chronic diseases such as Alzheimer's.

Clear Evidence the Drug Is Reaching Its Target

The study also provided direct evidence that enrupatinib is affecting neuroinflammation in the brain.

Researchers used TSPO-PET imaging, an advanced brain imaging technique that measures inflammation levels.

In a biomarker-selected subgroup, four out of five participants experienced reductions greater than 30% in neuroinflammation signals across multiple brain regions after treatment.

A statistically significant reduction was also observed in the Posterior Cingulate and Precuneus regions of the brain, areas known to be heavily affected in Alzheimer's disease.

In the broader group of participants who underwent PET imaging, 57% showed reductions in neuroinflammation after 28 days of treatment.

These findings provide strong evidence that enrupatinib is successfully engaging its intended biological target.

Early Signs of Cognitive Improvement

Although the study was not designed to measure treatment effectiveness on cognition at this stage, researchers observed an encouraging signal in one participant.

A patient who responded positively on TSPO-PET imaging showed improvements across all exploratory cognitive and functional assessments.

Most notably, this individual demonstrated an eight-point improvement in Mini-Mental State Examination (MMSE) score compared with baseline.

While this result comes from a single participant and should be interpreted cautiously, it raises the possibility that reducing neuroinflammation could translate into meaningful clinical improvements for some patients.

Larger studies will be needed to confirm whether this effect can be consistently reproduced.

Biomarker Discovery May Support Precision Medicine

Another important outcome from the interim analysis was the identification of a potential predictive biomarker.

Researchers found preliminary evidence suggesting that certain patients may be more likely to respond to enrupatinib treatment.

If validated in future studies, this biomarker could help identify patients most likely to benefit from therapy, improve clinical trial efficiency, and support a precision medicine approach to Alzheimer's treatment.

This type of patient selection strategy is becoming increasingly important in modern drug development, particularly for complex neurological diseases.

Company Leadership Sees Strong Potential

According to Dr. Hung-Kai Kevin Chen, Chief Executive Officer and Chief Medical Officer of Elixiron Immunotherapeutics, the interim findings delivered exactly the type of signals the company hoped to see.

The combination of strong safety results, meaningful target engagement, and early indications of cognitive benefit provides additional confidence in the therapeutic approach.

The company believes these results further strengthen the scientific rationale for targeting neuroinflammation as a way to modify the course of Alzheimer's disease.

Next Step: A Larger Placebo-Controlled Study

Based on the encouraging interim findings, Elixiron plans to move forward with a larger placebo-controlled study.

The upcoming trial will focus on patients identified through the predictive biomarker discovered during the current study. This approach is intended to enrich the study population with individuals most likely to respond to treatment.

The goal will be to further evaluate enrupatinib's safety and determine whether the neuroinflammation reductions observed can consistently translate into measurable cognitive benefits.

About the Phase 2 Study

The ongoing Phase 2 proof-of-concept trial is evaluating enrupatinib in patients with mild-to-severe Alzheimer's disease.

Participants receive oral enrupatinib at a dose of 448.2 mg twice daily for 28 days.

The primary objective of the study is to assess changes in neuroinflammation using TSPO-PET imaging. Researchers are also collecting exploratory data on cognitive function and daily living activities.

The trial is registered under NCT06745583 and receives support from the Alzheimer's Association's Part the Cloud initiative.

About Enrupatinib

Enrupatinib (EI-1071) is an investigational oral drug designed to penetrate the brain and selectively inhibit colony-stimulating factor 1 receptor (CSF-1R).

By regulating microglial activity, the drug aims to reduce the chronic neuroinflammation that contributes to Alzheimer's disease progression.

Researchers hope this mechanism may eventually provide a disease-modifying approach rather than simply treating symptoms.

Alzheimer's disease remains one of the most challenging neurological disorders, with millions of patients worldwide still lacking effective disease-modifying treatment options.

The interim results from Elixiron's Phase 2 study provide encouraging evidence that targeting neuroinflammation may represent a promising new direction for treatment.

While the findings remain preliminary, the combination of favorable safety data, measurable biological activity, and early cognitive signals offers an important foundation for future development.

As larger studies move forward, researchers will be watching closely to determine whether enrupatinib can deliver meaningful benefits for patients living with Alzheimer's disease.